RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Guangdi Wang to Antineoplastic Agents, Hormonal

This is a "connection" page, showing publications Guangdi Wang has written about Antineoplastic Agents, Hormonal.
Connection Strength

1.352
  1. Zhang C, Zhong Q, Zhang Q, Zheng S, Miele L, Wang G. Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer. Breast Cancer Res Treat. 2015 Jul; 152(2):283-91.
    View in: PubMed
    Score: 0.507
  2. Jiang Q, Zheng S, Wang G. Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer. Future Med Chem. 2013 Jun; 5(9):1023-35.
    View in: PubMed
    Score: 0.440
  3. Zhou C, Zhong Q, Rhodes LV, Townley I, Bratton MR, Zhang Q, Martin EC, Elliott S, Collins-Burow BM, Burow ME, Wang G. Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res. 2012 Mar 14; 14(2):R45.
    View in: PubMed
    Score: 0.405
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support